DSP-7888 + bevacizumab

DSP-7888 + bevacizumab is a combination therapy being investigated for the treatment of recurrent or progressive glioblastoma (GBM). DSP-7888 is an investigational WT1 immunotherapeutic cancer vaccine containing two peptides that induce WT1-specific cytotoxic T-lymphocytes (WT1-CTL) and helper T-cells to attack WT1-expressing cancerous cells found in various types of hematologic and solid tumors. Researchers have identified that adding a peptide to induce helper T-cells may improve outcomes compared to a treatment regimen based on a killer peptide alone. Bevacizumab is an FDA-approved therapy for GBM that is administered intravenously.

Other names

adegramotide/nelatimotide + bevacizumabombipepimut-S emulsion + bevacizumab